Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension

European Journal of Preventive Cardiology

Volumn 19, Issue 5, 2012, Pages 960-971

  Paolillo, Stefania ^a,b   Farina, Stefania ^b   Bussotti, Maurizio ^c   Iorio, Annamaria ^b,d   Filardi, Pasquale Perrone ^a   Piepoli, Massimo F ^e   Agostoni, Piergiuseppe ^b,f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^e GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cardiopulmonary exercise test; exercise test; Pulmonary arterial hypertension

Indexed keywords

CARBON DIOXIDE; CARBON MONOXIDE;

ANAEROBIC THRESHOLD; BODY WEIGHT; CARDIOPULMONARY EXERCISE TEST; CYCLING; DISEASE SEVERITY; END TIDAL CARBON DIOXIDE TENSION; EXERCISE TOLERANCE; FORCED VITAL CAPACITY; HEART LEFT RIGHT SHUNT; HEART RIGHT LEFT SHUNT; HUMAN; HYPOXEMIA; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG PRESSURE; LUNG VOLUME; MORBIDITY; OXYGEN SATURATION; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SPIROMETRY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TIDAL VOLUME; WALKING; DISEASE MANAGEMENT; EXERCISE TEST; METHODOLOGY; PHYSIOLOGY;

DISEASE MANAGEMENT; EXERCISE TEST; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY;

EID: 84873246507     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711426635     Document Type: Review

References (60)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 ; 30: 2493-2537
2. Mezzani A, Agostoni P, Cohen-Solal A, Corra U, Jegier A, Kouidi E, et al. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2009 ; 16: 249-267
3. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001 ; 104: 429-435
4. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009 ; 77: 3-17
5. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005 ; 127: 1637-1646
6. West JB. Ventilation-perfusion inequality and overall gas exchange in computer models of the lung. Respir Physiol. 1969 ; 7: 88-110
7. Naeije R, van de Borne P. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. Eur Respir J. 2009 ; 34: 792-794
8. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation. 2002 ; 105: 54-60
9. Deboeck G, Niset G, Lamotte M, Vachiery JL, Naeije R. Exercise testing in pulmonary arterial hypertension and in chronic heart failure. Eur Respir J. 2004 ; 23: 747-751
10. Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007 ; 29: 944-950
11. Cattadori G, Schmid JP, Brugger N, Gondoni E, Palermo P and Agostoni P. Hemodynamic effects of training exercise in heart failure. J Card Fail 2011; in press.
12. Kabitz HJ, Schwoerer A, Bremer HC, Sonntag F, Walterspacher S, Walker D, et al. Impairment of respiratory muscle function in pulmonary hypertension. Clin Sci (Lond). 2008 ; 114: 165-171
13. Agostoni P, Smith DD, Schoene RB, Robertson HT, Butler J. Evaluation of breathlessness in asbestos workers. Results of exercise testing. Am Rev Respir Dis. 1987 ; 135: 812-816
14. Sue DY, Oren A, Hansen JE, Wasserman K. Lung function and exercise performance in smoking and nonsmoking asbestos-exposed workers. Am Rev Respir Dis. 1985 ; 132: 612-618
15. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis. 1984 ; 129: S49 - S55
16. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. 2003 ; 41: 1028-1035
17. D'Alonzo GE, Bower JS, Dantzker DR. Differentiation of patients with primary and thromboembolic pulmonary hypertension. Chest. 1984 ; 85: 457-461
18. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 ; 115: 343-349
19. Steenhuis LH, Groen HJ, Koeter GH, van der Mark TW. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2000 ; 16: 276-281
20. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. 1981 ; 64: 1227-1234
21. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985 ; 132: 919-923
22. guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 ; 166: 111-117
23. Deboeck G, Niset G, Vachiery JL, Moraine JJ, Naeije R. Physiological response to the six-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2005 ; 26: 667-672
24. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000 ; 161: 487-492
25. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40: 780-788
26. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006 ; 114: 1482-1489
27. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353: 2148-2157
28. Langleben D, Brock T, Dixon R, Barst R. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol. 2004 ; 44 (Suppl 1). S80 - S84
29. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 ; 169: 441-447
30. Ulrich S, Speich R, Domenighetti G, Geiser T, Aubert JD, Rochat T, et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly. 2007 ; 137: 573-580
31. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008 ; 371: 2093-2100
32. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 ; 358: 1119-1123
33. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 ; 117: 3010-3019
34. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009 ; 30: 394-403
35. Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010 ; 159: 245-257
36. Farina S, Bussotti M, Agostoni P. The value of exercise testing in the diagnosis of pulmonary arterial hypertension. Turkish Thoracic Journal. 2008 ; 9: 167-173
37. Oudiz RJ, Barst RJ, Hansen JE, Sun XG, Garofano R, Wu X, et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol. 2006 ; 97: 123-126
38. Hansen JE, Sun XG, Yasunobu Y, Garafano RP, Gates G, Barst RJ, et al. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest. 2004 ; 126: 816-824
39. Wasserman K, Hansen JE, Sue DY, Whipp BJ Principles of exercise testing and interpretation. 4 th edn. Baltimore: Lippincott Williams and Wilkins, 1999; 77-106.
40. Agostoni P, Bianchi M, Moraschi A, Palermo P, Cattadori G, La Gioia R, et al. Work-rate affects cardiopulmonary exercise test results in heart failure. Eur J Heart Fail. 2005 ; 7: 498-504
41. Groepenhoff H, Westerhof N, Jacobs W, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Exercise stroke volume and heart rate response differ in right and left heart failure. Eur J Heart Fail. 2010 ; 12: 716-720
42. D'Alonzo GE, Gianotti LA, Pohil RL, Reagle RR, DuRee SL, Fuentes F, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987 ; 92: 57-62
43. Riley MS, Porszasz J, Engelen MP, Brundage BH, Wasserman K. Gas exchange responses to continuous incremental cycle ergometry exercise in primary pulmonary hypertension in humans. Eur J Appl Physiol. 2000 ; 83: 63-70
44. Laskey WK, Ferrari VA, Palevsky HI, Kussmaul WG. Pulmonary artery hemodynamics in primary pulmonary hypertension. J Am Coll Cardiol. 1993 ; 21: 406-412
45. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2006 ; 27: 114-120
46. Provencher S, Herve P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J. 2008 ; 32: 393-398
47. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, et al. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1995 ; 76: 1271-1276
48. Valli G, Vizza CD, Onorati P, Badagliacca R, Ciuffa R, Poscia R, et al. Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. Eur J Appl Physiol. 2008 ; 102: 417-424
49. Hansen JE, Ulubay G, Chow BF, Sun XG, Wasserman K. Mixed-expired and end-tidal CO2 distinguish between ventilation and perfusion defects during exercise testing in patients with lung and heart diseases. Chest. 2007 ; 132: 977-983
50. Agostoni P, Valentini M, Magri D, Revera M, Caldara G, Gregorini F, et al. Disappearance of isocapnic buffering period during increasing work rate exercise at high altitude. Eur J Cardiovasc Prev Rehabil. 2008 ; 15: 354-358
51. Guazzi M, Marenzi G, Assanelli E, Perego GB, Cattadori G, Doria E, et al. Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. J Card Fail. 1995 ; 1: 401-408
52. Agostoni P, Butler J Textbook of respiratory medicine. Murray JFE Nadel JA, ed. Boston: WB Saunders Company ; 1994: 943-962.
53. Smith DD, Agostoni PG. The discriminatory value of the P(A-a)O2 during exercise in the detection of asbestosis in asbestos exposed workers. Chest. 1989 ; 95: 52-55
54. Hollenberg M, Tager IB. Oxygen uptake efficiency slope: an index of exercise performance and cardiopulmonary reserve requiring only submaximal exercise. J Am Coll Cardiol. 2000 ; 36: 194-201
55. Sietsema KE, Cooper DM, Perloff JK, Child JS, Rosove MH, Wasserman K, et al. Control of ventilation during exercise in patients with central venous-to-systemic arterial shunts. J Appl Physiol. 1988 ; 64: 234-242
56. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002 ; 106: 319-324
57. Oudiz RJ, Midde R, Hovenesyan A, Sun XG, Roveran G, Hansen JE, et al. Usefulness of right-to-left shunting and poor exercise gas exchange for predicting prognosis in patients with pulmonary arterial hypertension. Am J Cardiol. 2010 ; 105: 1186-1191
58. Oudiz RJ, Roveran G, Hansen JE, Sun XG, Wasserman K. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail. 2007 ; 9: 917-921
59. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004 ; 24: 1007-1010
60. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest. 1999 ; 116: 914-920